Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus

Dipeptidyl Peptidase-4 Inhibitors Administered in Combination With Metformin Result in an Additive Increase in the Plasma Concentration of Active GLP-1

(2010) E M Migoya et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin

(2010) B. Ahrén et al.   DIABETES OBESITY & METABOLISM

Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice

(2010) A. Maida et al.   DIABETOLOGIA

Addition of metformin to exogenous glucagon-like peptide–1 results in increased serum glucagon-like peptide–1 concentrations and greater glucose lowering in type 2 diabetes mellitus

(2010) Joy Cuthbertson et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Metformin increases plasma ghrelin in Type 2 diabetes

(2009) Matthew P. Doogue et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Investigation of the effect of oral metformin on dipeptidylpeptidase-4 (DPP-4) activity in Type 2 diabetes

(2009) J. Cuthbertson et al.   DIABETIC MEDICINE

Metformin, but not pioglitazone, decreases postchallenge plasma ghrelin levels in type 2 diabetic patients: a possible role in weight stability?

(2008) I. Kusaka et al.   DIABETES OBESITY & METABOLISM